Akari Therapeutics, Plc
AKTX · NASDAQ
Market closed$11.01$-0.490000 (-4.26%)After hours $11.01 · 0.00%
Key statistics
Previous close$11.50
Open$11.18
Day high$11.64
Day low$10.70
52-week high$49.60
52-week low$3.02
Market cap12.60M
Volume42.19K
Average volume804.18K
P/E ratio-2.46
Forward P/E—
EPS-4.48
Dividend yield0.00%
Market context
Why it moved
AKTX shares declined amid broad selling pressure and a lack of fresh positive catalysts, with the stock retreating from recent highs as profit-taking and general market weakness weighed on the small-cap oncology company's shares.
What is happening
Recent company-specific developments and publisher coverage.
Barchart.com · July 14, 2026Akari Therapeutics (AKTX) Is Advancing the Next Generation of Antibody Drug Conjugates Through Novel Payload InnovationQuiver Quantitative · July 7, 2026Akari Therapeutics Appoints Patricia LoRusso to Scientific Advisory Board as Lead ADC Program Advances Toward First-in-Human TrialStock Titan · July 7, 2026Akari adds former AACR president Patricia LoRusso to advisory boardQuiver Quantitative · June 29, 2026Akari Therapeutics Completes Consolidated PIPE Closing, Receives $8.3 Million in Total Q2 2026 CapitalGuruFocus · May 22, 2026Akari Therapeutics (AKTX) Shares Surge 120% on Promising Preclinical Cancer Therapy DataSeeking Alpha · May 22, 2026Akari Therapeutics gains on positive preclinical data for cancer therapy (AKTX:NASDAQ)Quiver Quantitative · May 22, 2026Akari Therapeutics (AKTX) surges as new KRAS pancreatic cancer data and a $5.5M financing grab investor attentionInvesting.com · May 21, 2026Akari Therapeutics stock rockets 50% higher on KRAS combination data Benzinga · July 2, 2026Akari Therapeutics Files Prospectus Related To Resale Of Up To 6M ADSs Representing 480B Ordinary Shares By The Selling Shareholders Benzinga · May 28, 2026Akari Therapeutics CEO Highlights ASCO Data Demonstrating Synergy Of AKTX-101 With Adagasrib In KRAS-Driven Cancers In Virtual Investor "What This Means" Segment Benzinga · May 26, 2026Why Akari Therapeutics Stock Is Falling On Tuesday? Benzinga · May 22, 2026Akari Therapeutics Stock Jumps On Promising Preclinical Data Benzinga · May 21, 2026Akari Therapeutics' AKTX-101 Shows Synergistic Preclinical Cytotoxicity With KRAS Inhibitor In KRAS-Mutant Pancreatic Cancer Models, Highlighting RNA Splicing Payload Advantage Benzinga · May 21, 2026Akari Therapeutics Commences $5.5M Private Placement Benzinga · May 14, 2026Why Akari Therapeutics Stock Is Surging On Thursday? Benzinga · May 12, 2026Akari Therapeutics Granted European Patent For Proprietary ADC Payload Platform Technology